Overview
Evolent Health Q3 2025 revenue beats analyst expectations
Company announces over $500 mln in new annualized revenue for 2026
Outlook
Evolent expects Q4 2025 revenue between $462 mln and $472 mln
Company anticipates 2025 full-year revenue of $1.87 bln to $1.88 bln
Evolent forecasts prelim 2026 revenue to reach $2.5 bln
Result Drivers
NEW CONTRACTS - Evolent signed two new revenue agreements, totaling thirteen for the year, contributing to expected 2026 revenue growth
PRODUCT INNOVATIONS - Innovations in member navigation and Oncology Care Partners are driving growth, per CEO Seth Blackley
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $479.53 mln | $467.50 mln (14 Analysts) |
Q3 Net Income | -$26.93 mln | ||
Q3 Adjusted EBITDA | $38.96 mln | ||
Q3 Adjusted EBITDA Margin | 8.10% |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Evolent Health Inc is $15.50, about 59% above its November 5 closing price of $6.35
The stock recently traded at 28 times the next 12-month earnings vs. a P/E of 30 three months ago
Press Release: ID:nPn1LQBfwa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)